Home › Acute Myeloid Leukemia › Iowa
Acute Myeloid Leukemia clinical trials in Iowa
17 studies for Acute Myeloid Leukemia are looking for participants at sites in Iowa.
Cities in Iowa
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 28, 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic, Clive
- Iowa Methodist Medical Center, Des Moines
- and 7 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 22, 2026 · NCT05554406Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06317649A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Iowa Hospital, Iowa City
RecruitingPhase 1/2
30 Days · All sexes · Updated Sep 16, 2026 · NCT04065399Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Blank Children's Hospital, Des Moines
RecruitingPhase 3
Ages 1 to 25 · All sexes · Updated Sep 4, 2026 · NCT07022678Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- and 13 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- University of Iowa Hospital and Clinics, Iowa City
RecruitingObservational study
Ages 0 and older · All sexes · Updated Sep 2, 2026 · NCT07154823High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
- University of Iowa Health Care, Iowa City
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 31, 2026 · NCT07177079The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- University of Iowa Stead Family Children's Hospital, Iowa City
RecruitingPhase 3
29 Days – 21 Years · All sexes · Updated Aug 24, 2026 · NCT05183035Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Iowa Hospitals & Clinics, Iowa City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Iowa, Iowa City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Iowa Hospitals and Clinics, Iowa City
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 17, 2026 · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Iowa, Iowa City
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Iowa Hospitals & Clinics, Iowa City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.